Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 2/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | FRK | P42685 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826448 | 1.00 | ABCB1 (1.00) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13679699 | 0.96 | ABCB1 (0.92) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL3830858 | 0.96 | ABCB1 (0.92) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL3829640 | 0.95 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13679717 | 0.95 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13780563 | 0.95 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13679665 | 0.95 | ABCB1 (0.91) | ABCB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3824437 | 0.95 | ABCB1 (0.91) | ABCB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5468480 | 0.94 | ABCB1 (0.89) | ABCB1PTPN1MAPTNOX1MAPK11 | |
| SCHEMBL30357745 | 0.93 | ABCB1 (0.87) | ABCB1PTPN1MAPTNOX1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192503-A1 | NOVEL METHODS OF TREATING A NEURODEGENERATIVE DISEASE IN A MAMMAL IN NEED THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2019-06-27 | — | — | US | claimed |
| US-10258615-B2 | Methods of treating a neurodegenerative disease in a mammal in need thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2019-04-16 | — | — | US | claimed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| US-20250244341-A1 | Secreted P-glycoprotein is a Non-Invasive Biomarker of Chronic Rhinosinusitis | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-07-31 | — | — | US | disclosed |
| US-12268726-B2 | Treatment of rhinosinusitis with P-glycoprotein inhibitors | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-04-08 | — | — | US | disclosed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240148823-A1 | Treatment of Rhinosinusitis with P-glycoprotein Inhibitors | MASSACHUSETTS EYE & EAR INFIRMARY | 2024-05-09 | — | — | US | disclosed |
| US-11786574-B2 | Treatment of rhinosinusitis with p-glycoprotein inhibitors | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220362236-A1 | NOVEL METHODS OF TREATING A NEURODEGENERATIVE DISEASE IN A MAMMAL IN NEED THEREOF | UNIV JEFFERSON (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220257540-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | ANHUI RONGHANG BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| US-11408900-B2 | Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | disclosed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2211856-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | The Hospital For Sick Children (CA) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009073564-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-11 | — | — | WO | disclosed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ABCB1 3788/4885PTPN1 2752/4885MAPT 55/4885 |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | GAA, GBA1, LIPA | ABCB1 1406/4885PTPN1 4036/4885MAPT 691/4885 |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885PTPN1 3797/4885MAPT 26/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | ABCB1 14/4885PTPN1 3854/4885MAPT 39/4885 |
| US-20220257540-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | ABCB1, CYP7A1, CYP3A43 | ABCB1 1/4885PTPN1 2263/4885MAPT 376/4885 |
| US-12109219-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ABCB1 834/4885PTPN1 2395/4885MAPT 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.